ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Autor: | Patel H; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Periyasamy M; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Sava GP; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Bondke A; Department of Chemistry, Imperial College London, London, United Kingdom., Slafer BW; Department of Chemistry, Imperial College London, London, United Kingdom., Kroll SHB; Department of Chemistry, Imperial College London, London, United Kingdom., Barbazanges M; Department of Chemistry, Imperial College London, London, United Kingdom., Starkey R; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Ottaviani S; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Harrod A; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Aboagye EO; Comprehensive Cancer Imaging Centre, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Buluwela L; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom., Fuchter MJ; Department of Chemistry, Imperial College London, London, United Kingdom., Barrett AGM; Department of Chemistry, Imperial College London, London, United Kingdom., Coombes RC; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom. simak.ali@imperial.ac.uk c.coombes@imperial.ac.uk., Ali S; Division of Cancer, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom. simak.ali@imperial.ac.uk c.coombes@imperial.ac.uk. |
---|---|
Jazyk: | angličtina |
Zdroj: | Molecular cancer therapeutics [Mol Cancer Ther] 2018 Jun; Vol. 17 (6), pp. 1156-1166. Date of Electronic Publication: 2018 Mar 15. |
DOI: | 10.1158/1535-7163.MCT-16-0847 |
Abstrakt: | Recent reports indicate that some cancer types are especially sensitive to transcription inhibition, suggesting that targeting the transcriptional machinery provides new approaches to cancer treatment. Cyclin-dependent kinase (CDK)7 is necessary for transcription, and acts by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (PolII) to enable transcription initiation. CDK7 additionally regulates the activities of a number of transcription factors, including estrogen receptor (ER)-α. Here we describe a new, orally bioavailable CDK7 inhibitor, ICEC0942. It selectively inhibits CDK7, with an IC (©2018 American Association for Cancer Research.) |
Databáze: | MEDLINE |
Externí odkaz: |